European Biopharmaceutical Enterprises Announces New Partnership with
European Biotechnology Network to Strengthen Innovative Collaboration
Eco-system
(Brussels – 21 May): Today the European Biopharmaceutical Enterprises, EBE, is delighted to announce the
launch of a partnership with European Biotechnology Network, EBN, a fellow network dedicated to facilitating
cooperation between professionals in biotechnology and life sciences in Europe. The partnership will open up
EBN’s Funding Hub to members of EBE, and further the collaborative relationship between the two Brusselsbased associations, which have previously worked together to the benefit of members of both associations.
The EBN Funding Hub makes use of collaborative research funding to create cross-sectoral and industryacademia partnerships. In the four years of its operation, it has driven the creation of diverse partnerships.
Bringing the two networks together around the Funding Hub, members on both sides benefit from a
substantially increased pool of potential partners who proactively seek to build effective collaborations.
Dr Claire Skentelbery, Secretary General of EBN said: “Nothing focuses the mind like money and a deadline,
and the funding hub is an excellent tool to bring complementary science and business together around an
opportunity. Through the project development process, partners in effect do their due diligence on each
other. And even if the proposal is ultimately unsuccessful, you have built a strong partnership for future
opportunities. This was exactly the case for the IMI (Innovative Medicines Initiative) project successfully
supported by EBN, where a third proposal attempt from well-connected partners, delivered the successful
ND4BB project ENABLE (targeting anti-microbial resistance).”
Titta Rosvall-Puplett, Executive Director of EBE, stated: “Creation of a formal partnership with EBN brings
together two highly complementary networks. Following EBE’s recent strategy towards delivering unique
added value to its members and stakeholders, by expanding access to expertise and knowledge to regional and
national networks, I am delighted about this partnership with EBN.”
The expanded Funding Hub will focus on Horizon2020, IMI2, EraNets and the many other funding tools that
drive collaboration. Webinars, workshops and project-building activities will support these joint efforts
through 2014. In coming together, EBE and EBN will further a shared mission of building partnerships in the
biotech and life sciences sectors.
Roberto Gradnik stated: “I am delighted to continue heading the EBE Board at this exciting point of change.
Enhancing the EBE network will benefit members in their collaborative endeavours, and the biotechnology and
advanced therapies sector as a whole. I invite everyone to learn more about EBE in our new video (here)”.
Media Contact:
Titta Rosvall-Puplett, Executive Director, EBE ( titta.rosvall-puplett@ebe-biopharma.org, +32 472 55 94 87)
European Biopharmaceutical Enterprises (EBE), a specialised group of EFPIA
Leopold Plaza Building
Rue du Trône 108
BE-1050 Brussels
Belgium
T +32 2 626 25 61
communications@ebe-biopharma.org
www.ebe-biopharma.eu
VAT BE418762559
ABOUT EBE:
European Biopharmaceutical Enterprises, EBE, is the European Trade Association representing the views of
biopharmaceutical companies. EBE is a specialised group of EFPIA, European Federation of Pharmaceutical
Industries and Associations. EBE acts as Europe’s expert voice for emerging bioscience & technology and
leading platform for health innovation ecosystems. More: www.ebe-biopharma.eu. Twitter: EBE_EU
ABOUT EBN:
The European Biotechnology Network is dedicated to facilitating co-operation between professionals in
biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups,
universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver
partnerships. EBN delivers a Funding Hub, as part of work to deliver its mission, where collaborative funding
opportunities open to European organisations are tracked and used to build diverse, exploitation-oriented
projects and collaborations. www.european-biotechnology.net
European Biopharmaceutical Enterprises (EBE), a specialised group of EFPIA
Leopold Plaza Building
Rue du Trône 108
BE-1050 Brussels
Belgium
T +32 2 626 25 61
communications@ebe-biopharma.org
www.ebe-biopharma.eu
VAT BE418762559